scholarly journals The outcome of COVID-19 in patients with hematological malignancy

2021 ◽  
Author(s):  
Pınar Tığlıoğlu ◽  
Murat Albayrak ◽  
Mesut Tığlıoğlu ◽  
Hacer Berna Afacan Öztürk ◽  
Merih Reis Aras ◽  
...  
Keyword(s):  
Hematological Malignancy

scholarly journals Autopsy Proven Pulmonary Mucormycosis Due to Rhizopus microsporus in a Critically Ill COVID-19 Patient with Underlying Hematological Malignancy

2021 ◽  
Vol 7 (2) ◽  
pp. 88
Author(s):  
Christoph Zurl ◽  
Martin Hoenigl ◽  
Eduard Schulz ◽  
Stefan Hatzl ◽  
Gregor Gorkiewicz ◽  
...  
Keyword(s):  
Myeloid Leukemia ◽  
Distress Syndrome ◽  
Viral Infections ◽  
Hematological Malignancy ◽  
Pulmonary Infections ◽  
Rhizopus Microsporus ◽  
Pulmonary Aspergillosis ◽  
Pulmonary Mucormycosis ◽  
The Past ◽  
Secondary Acute Myeloid Leukemia

Viral infections can cause acute respiratory distress syndrome (ARDS), consequently leading to susceptibility for secondary pulmonary infections. Over the past few weeks, a number of studies have reported on secondary pulmonary aspergillosis complicating severe COVID-19. We report the case of a 53-year old male patient with secondary acute myeloid leukemia (AML) who suffered from COVID-19 ARDS and was diagnosed postmortem with mucormycosis.

scholarly journals Gain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma

Cancers ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 256
Author(s):  
Ichiro Hanamura
Keyword(s):  
Multiple Myeloma ◽  
Hematological Malignancy ◽  
Treatment Approach ◽  
Current Knowledge ◽  
Chromosome 1 ◽  
Plasma Cell Neoplasm ◽  
Chromosome Arm ◽  
Cell Neoplasm ◽  
Prognostic Implications ◽  
Tandem Duplications

Multiple myeloma (MM), a plasma cell neoplasm, is an incurable hematological malignancy characterized by complex genetic and prognostic heterogeneity. Gain or amplification of chromosome arm 1q21 (1q21+) is the most frequent adverse chromosomal aberration in MM, occurring in 40% of patients at diagnosis. It occurs in a subclone of the tumor as a secondary genomic event and is more amplified as the tumor progresses and a risk factor for the progression from smoldering multiple myeloma to MM. It can be divided into either 1q21 gain (3 copies) or 1q21 amplification (≥4 copies), and it has been suggested that the prognosis is worse in cases of amplification than gain. Trisomy of chromosome 1, jumping whole-arm translocations of chromosome1q, and tandem duplications lead to 1q21+ suggesting that its occurrence is not consistent at the genomic level. Many studies have reported that genes associated with the malignant phenotype of MM are situated on the 1q21 amplicon, including CKS1B, PSMD4, MCL1, ANP32E, and others. In this paper, we review the current knowledge regarding the clinical features, prognostic implications, and the speculated pathology of 1q21+ in MM, which can provide clues for an effective treatment approach to MM patients with 1q21+.

scholarly journals Challenging Diagnosis in NUT Carcinoma

2021 ◽  
pp. 106689692110195
Author(s):  
Grosse Claudia ◽  
Grosse Alexandra
Keyword(s):  
Nuclear Protein ◽  
Hematological Malignancy ◽  
Undifferentiated Carcinoma ◽  
Squamous Differentiation ◽  
Poorly Differentiated Carcinoma ◽  
Poorly Differentiated ◽  
Nut Carcinoma ◽  
Disseminated Disease ◽  
Generation Sequencing

Nuclear protein in testis (NUT) carcinoma represents a highly aggressive, poorly differentiated carcinoma that is genetically defined by rearrangement of NUT gene. The histomorphological appearance ranges from entirely undifferentiated carcinoma to carcinoma with prominent squamous differentiation. NUT carcinoma can display neuroendocrine features. Although it is typically distributed along the midline axis, it may manifest in nonmidline locations. The majority of patients develop rapidly disseminated disease. We illustrate 2 cases of NUT carcinoma, one located in the lung, which closely resembled a neuroendocrine carcinoma, and the other one with assumed lung origin demonstrating metastatic dissemination with diffuse bone involvement, which was clinically first suspected to be a hematological malignancy. Due to its undifferentiated nature, NUT carcinoma may be confused with many entities. NUT immunohistochemistry is considered to be sufficient for the diagnosis. Fluorescence in-situ hybridization analysis and next-generation sequencing are currently used to confirm the diagnosis.

Fertility preservation with IVF OR IVM for women with hematological malignancy – experiences and expectations

2012 ◽  
Vol 98 (3) ◽  
pp. S94
Author(s):  
J.H. Hyman ◽  
J.-T. Chung ◽  
T. Sokal-Arnon ◽  
E. Shalom-Paz ◽  
A. Wiser ◽  
...  
Keyword(s):  
Fertility Preservation ◽  
Hematological Malignancy

scholarly journals Clinico-hematological study of pancytopenia

1970 ◽  
Vol 2 (3) ◽  
pp. 207-210 ◽  
Author(s):  
A Lakhey ◽  
OP Talwar ◽  
VK Singh ◽  
Shiva Raj KC
Keyword(s):  
Bone Marrow ◽  
Teaching Hospital ◽  
Myeloid Leukemia ◽  
Hematological Malignancies ◽  
Hematological Malignancy ◽  
Complete Blood Count ◽  
Megaloblastic Anemia ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Erythroid Hyperplasia

Background: Pancytopenia refers to a reduction in all the three cellular elements of blood. The aim of this study was to identify the various causes of pancytopenia in patients attending to Manipal teaching hospital in Pokhara. Materials and Methods: This was a cross-sectional study, carried out in Manipal teaching hospital from August 2008 to August 2010. Fifty-four patients with pancytopenia were included in the study. Complete blood count, bone marrow aspirations and trephine biopsies were performed. Data were analyzed using SPSS 11.0 version. Results: Out of 54 cases, there were 16 cases (29.60%) of hypoplastic bone marrow, 15 cases (27.78%) of hematological malignancies, 13 cases (24.10%) of megaloblastic anemia, 4 cases (11.11%) of erythroid hyperplasia and 6 cases (7.41%) of normcellular bone marrow. Acute myeloid leukemia was the commonest hematological malignancy. Conclusion: The commonest cause of pancytopenia in our study was hypoplastic bone marrow followed by hematological malignancies and megaloblastic anemia. DOI: http://dx.doi.org/10.3126/jpn.v2i3.6023 JPN 2012; 2(3): 207-210

Sign in / Sign up

Export Citation Format

Share Document